Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.70
NUVA's Cash to Debt is ranked higher than
61% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. NUVA: 0.70 )
NUVA' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 0.7

Equity to Asset 0.49
NUVA's Equity to Asset is ranked higher than
57% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NUVA: 0.49 )
NUVA' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.93
Current: 0.49

0.36
0.93
Interest Coverage 1.22
NUVA's Interest Coverage is ranked lower than
61% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. NUVA: 1.22 )
NUVA' s 10-Year Interest Coverage Range
Min: 1.22   Max: 9999.99
Current: 1.22

1.22
9999.99
F-Score: 5
Z-Score: 2.38
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.53
NUVA's Operating margin (%) is ranked higher than
63% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. NUVA: 0.53 )
NUVA' s 10-Year Operating margin (%) Range
Min: -27436.54   Max: 6.71
Current: 0.53

-27436.54
6.71
Net-margin (%) -1.21
NUVA's Net-margin (%) is ranked higher than
61% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. NUVA: -1.21 )
NUVA' s 10-Year Net-margin (%) Range
Min: -27211.54   Max: 16.37
Current: -1.21

-27211.54
16.37
ROE (%) -1.51
NUVA's ROE (%) is ranked higher than
62% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. NUVA: -1.51 )
NUVA' s 10-Year ROE (%) Range
Min: -322.04   Max: 21.43
Current: -1.51

-322.04
21.43
ROA (%) -0.75
NUVA's ROA (%) is ranked higher than
63% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. NUVA: -0.75 )
NUVA' s 10-Year ROA (%) Range
Min: -768.33   Max: 10.76
Current: -0.75

-768.33
10.76
ROC (Joel Greenblatt) (%) 1.27
NUVA's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. NUVA: 1.27 )
NUVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -737.95   Max: 17.53
Current: 1.27

-737.95
17.53
Revenue Growth (%) 11.70
NUVA's Revenue Growth (%) is ranked higher than
86% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. NUVA: 11.70 )
NUVA' s 10-Year Revenue Growth (%) Range
Min: -40.2   Max: 486.2
Current: 11.7

-40.2
486.2
EBITDA Growth (%) 12.10
NUVA's EBITDA Growth (%) is ranked higher than
86% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. NUVA: 12.10 )
NUVA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 22.7
Current: 12.1

0
22.7
EPS Growth (%) -53.80
NUVA's EPS Growth (%) is ranked higher than
50% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NUVA: -53.80 )
NUVA' s 10-Year EPS Growth (%) Range
Min: -66.3   Max: 31
Current: -53.8

-66.3
31
» NUVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NUVA Guru Trades in Q3 2013

Steven Cohen 578,930 sh (+59.99%)
Mario Gabelli 90,700 sh (+49.42%)
Jim Simons 227,788 sh (+34.56%)
PRIMECAP Management 914,000 sh (+11.18%)
Joel Greenblatt 68,823 sh (+2.58%)
Ken Fisher 379,650 sh (+0.73%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Paul Tudor Jones 18,600 sh (-91.05%)
» More
Q4 2013

NUVA Guru Trades in Q4 2013

Louis Moore Bacon 25,000 sh (New)
Mario Gabelli 115,700 sh (+27.56%)
Jim Simons 261,788 sh (+14.93%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
PRIMECAP Management 914,000 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 367,150 sh (-3.29%)
Steven Cohen 482,285 sh (-16.69%)
Paul Tudor Jones 11,600 sh (-37.63%)
» More
Q1 2014

NUVA Guru Trades in Q1 2014

Jim Simons 346,527 sh (+32.37%)
Mario Gabelli 125,700 sh (+8.64%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
PRIMECAP Management 914,000 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 361,300 sh (-1.59%)
Steven Cohen 405,000 sh (-16.02%)
Paul Tudor Jones 8,800 sh (-24.14%)
» More
Q2 2014

NUVA Guru Trades in Q2 2014

Paul Tudor Jones 13,082 sh (+48.66%)
Mario Gabelli 155,700 sh (+23.87%)
Steven Cohen 437,000 sh (unchged)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Jim Simons 344,488 sh (-0.59%)
PRIMECAP Management 906,000 sh (-0.88%)
Ken Fisher 336,395 sh (-6.89%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-06-30 Add 23.87%0.01%$32.26 - $39.25 $ 35.734%155700
Joel Greenblatt 2013-12-31 Sold Out 0.06%$24.07 - $33.52 $ 35.7319%0
Mario Gabelli 2013-12-31 Add 27.56%$24.07 - $33.52 $ 35.7319%115700
Mario Gabelli 2013-09-30 Add 49.42%$22.82 - $26.99 $ 35.7345%90700
Joel Greenblatt 2013-06-30 Reduce -38.01%0.05%$19.93 - $24.79 $ 35.7363%67093
Mario Gabelli 2013-06-30 Add 32.82%$19.93 - $24.79 $ 35.7363%60700
Joel Greenblatt 2013-03-31 Add 37.81%0.03%$15.46 - $21.31 $ 35.7396%108240
Mario Gabelli 2013-03-31 Add 42.81%$15.46 - $21.31 $ 35.7396%45700
Ken Fisher 2013-03-31 Reduce -23.45%$15.46 - $21.31 $ 35.7396%355475
Joel Greenblatt 2012-12-31 New Buy0.07%$12.65 - $23.01 $ 35.73145%78542
Ken Fisher 2012-12-31 Add 34.48%0.01%$12.65 - $23.01 $ 35.73145%464375
PRIMECAP Management 2012-12-31 Add 34.88%$12.65 - $23.01 $ 35.73145%669000
Mario Gabelli 2012-12-31 Add 88.24%$12.65 - $23.01 $ 35.73145%32000
Ken Fisher 2012-09-30 New Buy0.02%$19.61 - $25.71 $ 35.7360%345302
Mario Gabelli 2012-03-31 Add 21.43%$11.35 - $17.56 $ 35.73147%17000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.69
NUVA's P/B is ranked higher than
74% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. NUVA: 2.69 )
NUVA' s 10-Year P/B Range
Min: 0.98   Max: 10.93
Current: 2.69

0.98
10.93
P/S 2.35
NUVA's P/S is ranked higher than
74% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. NUVA: 2.35 )
NUVA' s 10-Year P/S Range
Min: 0.86   Max: 10.64
Current: 2.35

0.86
10.64
PFCF 28.36
NUVA's PFCF is ranked higher than
86% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 623.33 vs. NUVA: 28.36 )
NUVA' s 10-Year PFCF Range
Min: 6.98   Max: 188.94
Current: 28.36

6.98
188.94
EV-to-EBIT 466.30
NUVA's EV-to-EBIT is ranked higher than
66% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 35.69 vs. NUVA: 466.30 )
NUVA' s 10-Year EV-to-EBIT Range
Min: 20.9   Max: 484.8
Current: 466.3

20.9
484.8
Current Ratio 3.69
NUVA's Current Ratio is ranked higher than
79% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NUVA: 3.69 )
NUVA' s 10-Year Current Ratio Range
Min: 1.58   Max: 15.05
Current: 3.69

1.58
15.05
Quick Ratio 2.70
NUVA's Quick Ratio is ranked higher than
78% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. NUVA: 2.70 )
NUVA' s 10-Year Quick Ratio Range
Min: 1.14   Max: 13.9
Current: 2.7

1.14
13.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.27
NUVA's Price/Tangible Book is ranked higher than
74% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. NUVA: 4.27 )
NUVA' s 10-Year Price/Tangible Book Range
Min: 2.36   Max: 34.31
Current: 4.27

2.36
34.31
Price/DCF (Projected) 1.90
NUVA's Price/DCF (Projected) is ranked higher than
86% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 28.89 vs. NUVA: 1.90 )
NUVA' s 10-Year Price/DCF (Projected) Range
Min: 1.21   Max: 25.15
Current: 1.9

1.21
25.15
Price/Median PS Value 0.71
NUVA's Price/Median PS Value is ranked higher than
90% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. NUVA: 0.71 )
NUVA' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.79
Current: 0.71

0.3
2.79
Earnings Yield (Greenblatt) 0.20
NUVA's Earnings Yield (Greenblatt) is ranked lower than
55% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. NUVA: 0.20 )
NUVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 4.8
Current: 0.2

0.2
4.8
Forward Rate of Return (Yacktman) 1.32
NUVA's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.54 vs. NUVA: 1.32 )
NUVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8   Max: 1.7
Current: 1.32

-8
1.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:NK8.Germany
Nuvasive Inc, was incorporated in Delaware in July 1997. The Company is a medical device company engaged in developing minimally disruptive surgical products and procedures for the spine. The Company's currently-marketed product portfolio is engaged in applications for spine fusion surgery, including biologics. The Company's main product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as an offering of biologics, cervical, motion preservation products, and Intra-Operative Monitoring (IOM) services. Its spine surgery product line offerings, which include products for the thoracolumbar spine, the cervical spine, and a set of motion preservation product offerings still under development, are mainly used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. Its biologic product line offerings include allograft, (donated human tissue) — Triad , and Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, FormaGraft, a collagen synthetic product used to aid the fusion process, and AttraX, a synthetic bone graft material, which is still in the process of U.S. regulatory clearance, to aid in spinal fusion. Its MAS platform, with the unique advantages provided by its nerve monitoring systems, enables an innovative lateral procedure known as eXtreme Lateral Interbody Fusion, or XLIF, in which surgeons access the spine for a fusion procedure from the side of the patient's body, rather than from the front or back. Its MaXcess instruments provide access to the spine in a manner that affords direct visualization and its nerve monitoring systems allow surgeons to avoid critical nerves. Its cervical product offering now provides a full set of solutions for cervical fusion surgery, including allograft and CoRoent implants, as well as cervical plating and posterior fixation products, and a set of motion preservation product offerings still under development. The Company competes with Medtronic Sofamor Danek (Medtronic), Natus, Cadwell Laboratories, and VIASYS Healthcare, a division of CareFusion Corporation DePuy, Stryker Spine and Synthes, Inc. The Company's products,medical devices and tissues subject to regulation by the FDA and other regulatory bodies.
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
NuVasive(R) Demonstrates Expanding EMEA Business at Eurospine 2014 With Surgeon Workshops and Innova Oct 15 2014 
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 
Weekly Guru Bargains Highlights: ASIA , SAY , VRX , AMLN , NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: ASIA, SAY, VRX, AMLN, NUVA Jan 01 2011 
Three Stocks for 2011: NUVA, ENOC, CBK Nov 25 2010 
NuVasive Inc. Reports Operating Results (10-Q) Nov 05 2010 
NuVasive Inc. Reports Operating Results (10-Q) Aug 06 2010 
NuVasive Inc. (NUVA) CEO and Chairman Alexis V Lukianov sells 5,000 Shares Jul 12 2010 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 5,000 Shares Jun 22 2010 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK